Navigation Links
Odyssey Thera to Participate in Expanded EPA Initiative
Date:12/6/2010

SAN RAMON, Calif., Dec. 6, 2010 /PRNewswire/ -- The United States Environmental Protection Agency (EPA) announced today a new phase of toxicity screening, in which 1,000 chemicals will be screened as part of EPA's ToxCast initiative. Odyssey Thera's participation in this program, first announced earlier this year, involves the application of extensive and diverse proprietary assay and screening technologies. "The Odyssey team is very pleased with our contributions to ToxCast to date, and we're excited to see this program accelerating," said Dr. Jane E. Lamerdin, Executive Director of R&D at Odyssey Thera, "ToxCast represents an ideal application of our validated chemical analysis strategies."

The chemicals will be assessed for potential toxicity to people and the environment. ToxCast is designed to determine how chemical exposures impact human biological processes and how the chemicals most likely lead to health effects. When fully implemented, ToxCast will be able to screen thousands of chemicals in fast, cost-effective tests that are relevant to human health. The chemicals being tested are found in industrial and consumer products, food additives and drugs that never made it to the market.

The full news release can be found at: http://yosemite.epa.gov/opa/admpress.nsf/d0cf6618525a9efb85257359003fb69d/73ec2518e34bc93d852577eb0060dd7c!OpenDocument. More information on ToxCast and the list of chemicals can be found at http://www.epa.gov/comptox.

About Odyssey Thera, Inc.

Odyssey Thera, Inc. is a privately held drug discovery technology company focused on improving the success rate of new therapeutic development. Odyssey Thera's technology measures disease–relevant pathway activity within living human cells. Odyssey is leveraging its proprietary drug discovery and development platform for internal programs and for premier pharmaceutical and biotechnology company partners. Patents owned by Odyssey also cover the use of the technology in live animals, plants and for diagnostic and bioprocess applications. To learn more about Odyssey Thera, please visit www.odysseythera.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
2. Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
3. Odyssey Thera Announces Achievement of Pfizer Drug Candidate Milestones
4. Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
5. Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy
6. Halozyme Therapeutics Realigns Management
7. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
8. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
9. SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies
10. VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
11. Neuro Kinetics Receives HHS Therapeutic Discovery Grant to Further Research Into Early Diagnosis of Sports Concussions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):